Brendan Griffin

Chief Financial Officer

Brendan M. Griffin has broad expertise in life sciences, drug development, strategic finance, M&A, and business strategy. With 20 years of experience in driving and funding innovation, Brendan most recently served as the Chief Financial Officer at Propella Therapeutics, an Astellas company, where he worked on post-merger integration activities after Propella’s acquisition by Astellas. Prior to that, Brendan helped lead the sale of Propella to Astellas Pharmaceuticals after running a dual-track process, during which Propella also secured an oversubscribed venture capital financing round. As an investment banker, Mr Griffin provided capital markets and advisory services to clients across North America, Asia, and Europe and was a senior member of the biotechnology investment banking team at Leerink Partners, where he completed over 100 transactions, including more than 20 IPOs.

Brendan holds a Master of Business Administration degree from Carnegie Mellon.